Arrowhead Pharmaceuticals presents new findings on Redemplo for severe hypertriglyceridemia, highlighting safety and dosing as potential differentiators against Ionis Pharmaceuticals. Analysts remain divided on the implications for market competition.
Safety and dosing are likely to be “key differentiators” for Arrowhead Pharmaceuticals as it looks to challenge Ionis Pharmaceuticals’ lead in the severe hypertriglyceridemia market.
Original title: “Arrowhead's new Redemplo findings in severe hypertriglyceridemia have analysts split”